Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.
相关临床试验
13
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2016
进行中（未招募）
1
7.7%
已完成
1
7.7%
尚未招募
1
7.7%
招募中
10
76.9%
暂无批准数据
- Elevar Therapeutics has filed a marketing authorization application with the European Medicines Agency for lirafugratinib as second-line treatment of advanced or metastatic FGFR2 fusion-positive cholangiocarcinoma. - The filing rests on Phase 1/2 ReFocus data showing a 46.5% objective response rate by independent review, with median duration of response of 11.8 months. - Median progression-free survival reached 11.3 months and median overall survival 22.8 months in patients who had received one prior line of systemic therapy. - The highly selective irreversible FGFR2 inhibitor is already under FDA Priority Review with a PDUFA target action date of Sept. 25, 2026, and is being studied tumor-agnostically in the Phase 2 ReFocus202 trial.
- Elevar Therapeutics filed a marketing authorization application with the European Medicines Agency for lirafugratinib as a second-line treatment for FGFR2-driven advanced or metastatic cholangiocarcinoma. - The filing rests on global Phase 1/2 data showing a 46.5% objective response rate, 11.8-month median duration of response, 11.3-month median PFS and 22.8-month median OS. - Lirafugratinib's selective FGFR2 inhibition yielded hyperphosphatemia and diarrhea rates of 20.7% and 21.6%, which the company cites as differentiated tolerability versus first-generation FGFR inhibitors. - The EMA submission follows a January FDA new drug application under priority review with a PDUFA deadline of the 25th of this month, while a tumor-agnostic Phase 2 trial targets a 2027 interim analysis.
- Goldman Sachs analyst Asad Haider reiterated a Buy rating on Eli Lilly with a $1,283.00 price target, reflecting continued confidence in the pharmaceutical giant. - Truist Financial's Srikripa Devarakonda also maintained a Buy rating on Eli Lilly, with shares trading at $1,163.73 as of early June. - The overall analyst consensus on Eli Lilly remains a Strong Buy with an average price target of approximately $1,267, implying an 11-19% upside from current levels. - In contrast, Replimune Group received a Hold rating from J.P. Morgan with a $8.00 target, while Novartis garnered a Hold from TD Cowen at $180.00.
- Zovegalisib combined with fulvestrant demonstrated consistent efficacy across different patient subgroups with PI3Kα-mutated, HR+/HER2- metastatic breast cancer, achieving 10.3-month median progression-free survival in all patients. - The drug showed broad activity regardless of prior SERD exposure or ESR1 mutation status, with objective response rates ranging from 39% to 60% across different patient populations. - Phase 3 ReDiscover-2 trial continues enrollment while the company advances dose escalation studies to inform future frontline metastatic treatment regimens.
- Drug Hunter, a knowledge platform serving over 200 pharmaceutical R&D organizations including Eli Lilly, Biogen, and NIH, announced seed funding led by Teamworthy Ventures to accelerate drug discovery insights. - The platform provides searchable insights from scientific literature, patents, and early disclosures, helping researchers make better-informed decisions and avoid costly mistakes in drug development. - Industry leaders from Isomorphic Labs, Biogen, and other major organizations describe Drug Hunter as an indispensable tool for accelerating decision-making and surfacing novel ideas. - The funding will support expanded scientific coverage, enhanced chemical structure databases, improved search analytics tools, and development of a mobile application for immediate disclosure highlights.
- Relay Therapeutics initiated the Phase 3 ReDiscover-2 trial for RLY-2608, a pan-mutant selective PI3Kα inhibitor targeting breast cancer patients with high unmet medical needs. - Updated ASCO 2025 data showed RLY-2608 achieved a median progression-free survival of 10.3 months and 39% objective response rate in PI3Kα-mutated, HR+/HER2- metastatic breast cancer patients. - The company reduced R&D expenses by 30.5% year-over-year while maintaining $656.8 million in cash reserves, projected to fund operations into 2029.
- Major pharmaceutical and biotech companies including Pfizer, Johnson & Johnson, Fate Therapeutics, and Generation Bio are implementing workforce reductions as part of industry-wide financial restructuring efforts. - Companies are shifting from broad R&D portfolios to focused pipeline optimization, with firms like Shattuck Labs and Relay Therapeutics narrowing their therapeutic focus to core projects with highest potential returns. - The layoffs reflect strategic responses to investor pressure for capital discipline, post-pandemic demand shifts, and the need to extend cash reserves while maintaining progress on lead clinical programs. - Industry consolidation and increased outsourcing to contract research organizations are driving operational realignment, as companies seek to reduce overhead costs and access specialized expertise without maintaining high-cost facilities.
- Isomorphic Labs, the AI-first drug discovery company, has appointed Dr. Ben Wolf as Chief Medical Officer to lead translation of AI-driven discoveries into clinical medicines. - Dr. Wolf brings nearly 20 years of biopharmaceutical experience, including expertise in precision oncology and advancing therapeutics from discovery through regulatory approval. - The company has established a new US presence in Cambridge, Massachusetts, following a $600 million external investment round earlier this year. - The appointment positions Isomorphic Labs to advance its AI drug design engine across multiple therapeutic areas and drug modalities into clinical development.
- Relay Therapeutics presented updated interim data for RLY-2608 plus fulvestrant showing consistent median progression-free survival of 11.0 months in second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. - The first-in-human ReDiscover study enrolled 118 patients, with RLY-2608 demonstrating a favorable tolerability profile including 92% median dose intensity and only 36% experiencing Grade 3 treatment-related adverse events. - The company plans to initiate the pivotal Phase 3 ReDiscover-2 trial in mid-2025, marking the first mutant-selective PI3Kα inhibitor to advance to Phase 3 testing. - RLY-2608 represents a novel allosteric, pan-mutant, and isoform-selective approach to PI3Kα inhibition, potentially addressing over 300,000 patients annually in the United States.
- Relay Therapeutics plans to initiate ReDiscover-2, a Phase 3 trial evaluating RLY-2608 plus fulvestrant in PI3Kα-mutated, HR+/HER2- advanced breast cancer patients, with enrollment target of 540 patients. - Interim Phase 1b data showed promising results with RLY-2608 plus fulvestrant achieving 11.4-month median progression-free survival in second-line treatment and 39% confirmed overall response rate. - The company maintains strong financial position with approximately $780 million in cash reserves as of Q4 2024, sufficient to fund operations into second half of 2027.
